Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: standardization is needed

Breast Cancer Research and Treatment
Hirofumi MukaiNoriyuki Katsumata

Abstract

Evaluation of the safety and efficacy of a combination of docetaxel and doxorubicin in breast cancer patients. Evaluation and comparison of the pathological complete response (pCR) to this regimen according to various definitions in different clinical trials. Utilize the data to propose standardization of definitions. Between 1998 and 2001, 141 patients with stage II (tumor size >3.0 cm) or III breast cancer were treated with doxorubicin 50 mg/m(2) followed by docetaxel 60 mg/m(2 )(AT) on day 1. A total of 4 courses of AT were administered as primary chemotherapy with intervals of 3 weeks. Additionally, 2 cycles of the same regimen were administered after surgery when clinical CR or PR was achieved; otherwise, 4 cycles of CMF were added postoperatively. 141 patients were enrolled in this trial. A clinical response rate was 86%. Seven patients (5%) achieved pCR according to the Japanese Breast Cancer Society classification, 14 patients (10%) fulfilled the University of Texas M.D. Anderson Cancer Center trial's pCR criteria, and 19 patients (14%) met the NSABP trial pCR definition. NCI CTC version 2 grade 3/4 toxicities included leucopenia (26%), neutropenia (85%) and febrile neutropenia (12%). Primary chemotherapy with AT induce...Continue Reading

References

Apr 1, 1991·British Journal of Cancer·E D AndersonU Chetty
Jan 28, 1983·Deutsche medizinische Wochenschrift·M Kaufmann, F Kubli
Jul 1, 1995·CA: a Cancer Journal for Clinicians·G BonadonnaB Salvadori
Feb 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I E SmithS Ebbs
Oct 1, 1994·Geburtshilfe und Frauenheilkunde·H P SinnH F Otto
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S M SchollP Beuzeboc
Dec 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P M RavdinR E Bellet
Dec 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V ValeroG N Hortobagyi
Mar 1, 1996·Primary Care·A E Harrison, V M Silenzio
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B FisherH D Bear
Dec 23, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A MakrisH T Ford
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M KuererS E Singletary
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G von MinckwitzM Kaufmann
Feb 17, 2001·Breast Cancer : the Journal of the Japanese Breast Cancer Society·M KurosumiUNKNOWN Commitee for Production of Histopathological Criteria, Japanese Breast Cancer Society
Aug 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G von MinckwitzUNKNOWN German Preoperative Adriamycin-Docetaxel and German Adjuvant Breast Cancer Study Groups
Nov 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A van der HageL Duchateau
Mar 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian C SmithKeith N Ogston
Aug 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marjorie C GreenGabriel N Hortobagyi
Feb 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jacek A KopecNorman Wolmark

❮ Previous
Next ❯

Citations

Jan 26, 2013·Journal of the National Cancer Institute·Cynthia A Thomson, Patricia A Thompson
Apr 30, 2014·European Journal of Nuclear Medicine and Molecular Imaging·Kenneth E PengelKenneth G A Gilhuijs
Apr 23, 2015·Critical Reviews in Oncology/hematology·Qian Wang-LopezJean-Marc Nabholtz
Feb 26, 2013·Cancer Treatment Reviews·Susan DentSacha Howell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Harold J BursteinRajendra Badwe
Annals of Oncology : Official Journal of the European Society for Medical Oncology
S AebiESMO Guidelines Working Group
Journal of the National Cancer Institute
Davide MauriJohn P A Ioannidis
© 2021 Meta ULC. All rights reserved